Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis.

ABSTRACT:

Background

Increased subchondral bone turnover may contribute to pain in osteoarthritis (OA).

Objectives

To investigate the analgesic potential of a modified version of osteoprotegerin (osteoprotegerin-Fc (OPG-Fc)) in the monosodium iodoacetate (MIA) model of OA pain.

Methods

Male Sprague Dawley rats (140-260 g) were treated with either OPG-Fc (3 mg/kg, subcutaneously) or vehicle (phosphate-buffered saline) between days 1 and 27 (pre-emptive treatment) or days 21 and 27 (therapeutic treatment) after an intra-articular injection of MIA (1 mg/50 µl) or saline. A separate cohort of rats received the bisphosphonate zoledronate (100 µg/kg, subcutaneously) between days 1 and 25 post-MIA injection. Incapacitance testing and von Frey (1-15 g) hind paw withdrawal thresholds we

SUBMITTER: Sagar DR 

PROVIDER: S-EPMC4112443 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature